RxDoctor Payments Data

Diane Wilder, MD

Hematology & Oncology · Little Rock, ARNPI 1619959525

Payments from drug & device makers

$227in general payments, 2019–2025

Across 9 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$99
  • AstraZeneca$26
  • Acrotech Biopharma Inc.$26
  • Pfizer$25
  • Epizyme, Inc.$23
  • Johnson & Johnson$16
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$167%
  • Education$21193%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$227 in reported general payments places this provider in the 10th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$5,236,085
Medicare patients
1,427
Services billed
222,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib52$828,242
TagrissoOsimertinib Mesylate48$800,161
Neulasta OnproPegfilgrastim80$590,915
VerzenioAbemaciclib37$554,519
FotivdaTivozanib Hcl14$433,057
CabometyxCabozantinib S-Malate20$372,800
TrazimeraTrastuzumab-Qyyp66$289,860
OrserduElacestrant Hcl12$283,294
MvasiBevacizumab-Awwb33$155,535
OgivriTrastuzumab-Dkst22$76,941
XgevaDenosumab22$68,184
EliquisApixaban104$65,606
Fulvestrant102$63,672
OntruzantTrastuzumab-Dttb12$58,560
ProcritEpoetin Alfa24$53,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Trazimera, Eliquis$25$1,183,708222 claims
AstraZenecaTagrisso$26$800,16148 claims
Johnson & JohnsonProcrit$16$53,65624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →